183 related articles for article (PubMed ID: 11474224)
21. Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients.
Navarro JF; Mora C; Muros M; García J
Nephrol Dial Transplant; 2006 Dec; 21(12):3428-34. PubMed ID: 16935891
[TBL] [Abstract][Full Text] [Related]
22. Urine IgM-excretion as a prognostic marker for progression of type 2 diabetic nephropathy.
Tofik R; Torffvit O; Rippe B; Bakoush O
Diabetes Res Clin Pract; 2012 Jan; 95(1):139-44. PubMed ID: 22078636
[TBL] [Abstract][Full Text] [Related]
23. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients.
Bolignano D; Lacquaniti A; Coppolino G; Donato V; Fazio MR; Nicocia G; Buemi M
Kidney Blood Press Res; 2009; 32(2):91-8. PubMed ID: 19321980
[TBL] [Abstract][Full Text] [Related]
24. Early detection of diabetic nephropathy and criteria for the initiation of therapy.
Tetsutani T; Yamaguchi T; Kadono K; Iida R; Yasunaga K
Nephron; 1993; 64(1):69-74. PubMed ID: 8502339
[TBL] [Abstract][Full Text] [Related]
25. Plasma serotonin is a predictor for deterioration of urinary albumin excretion in men with type 2 diabetes mellitus.
Fukui M; Shiraishi E; Tanaka M; Senmaru T; Sakabe K; Harusato I; Hasegawa G; Nakamura N
Metabolism; 2009 Aug; 58(8):1076-9. PubMed ID: 19416792
[TBL] [Abstract][Full Text] [Related]
26. Urinary excretion of podocytes in patients with diabetic nephropathy.
Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Ebihara I; Koide H
Nephrol Dial Transplant; 2000 Sep; 15(9):1379-83. PubMed ID: 10978394
[TBL] [Abstract][Full Text] [Related]
27. Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy.
Koshimura J; Fujita H; Narita T; Shimotomai T; Hosoba M; Yoshioka N; Kakei M; Fujishima H; Ito S
Biochem Biophys Res Commun; 2004 Mar; 316(1):165-9. PubMed ID: 15003525
[TBL] [Abstract][Full Text] [Related]
28. NLRP3 expression and urinary HSP72 in relation to biomarkers of inflammation and oxidative stress in diabetic nephropathy patients.
El-Horany HE; Abd-Ellatif RN; Watany M; Hafez YM; Okda HI
IUBMB Life; 2017 Aug; 69(8):623-630. PubMed ID: 28631886
[TBL] [Abstract][Full Text] [Related]
29. Oxidative stress markers in type 2 diabetes patients with diabetic nephropathy.
Chou ST; Tseng ST
Clin Exp Nephrol; 2017 Apr; 21(2):283-292. PubMed ID: 27233502
[TBL] [Abstract][Full Text] [Related]
30. Comparison of renal resistive index among patients with Type 2 diabetes with different levels of creatinine clearance and urinary albumin excretion.
Afsar B; Elsurer R
Diabet Med; 2012 Aug; 29(8):1043-6. PubMed ID: 22269249
[TBL] [Abstract][Full Text] [Related]
31. Comparison of urinary excretion of albumin, alpha 1-microglobulin and retinol-binding protein in diabetic patients.
Galanti LM; Jamart J; Dell'omo J; Donckier J
Diabetes Metab; 1996 Oct; 22(5):324-30. PubMed ID: 8896994
[TBL] [Abstract][Full Text] [Related]
32. [Can urine albumin/creatinine ratio replace 24 hours urinary albumin?].
Liu R; Zhu H; Yang JH; Gao ZA; Yuan XX; Li XC; Wang JY; Chang BC
Zhonghua Nei Ke Za Zhi; 2019 May; 58(5):377-381. PubMed ID: 31060147
[No Abstract] [Full Text] [Related]
33. Urinary platelet-derived growth factor-BB as an early marker of nephropathy in patients with type 2 diabetes: an Egyptian study.
Bessa SS; Hussein TA; Morad MA; Amer AM
Ren Fail; 2012; 34(6):670-5. PubMed ID: 22486214
[TBL] [Abstract][Full Text] [Related]
34. Distinct Biomarkers for Early Diagnosis of Diabetic Nephropathy.
Kishore L; Kaur N; Singh R
Curr Diabetes Rev; 2017; 13(6):598-605. PubMed ID: 27924722
[TBL] [Abstract][Full Text] [Related]
35. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus.
Kim NH; Kim KB; Kim DL; Kim SG; Choi KM; Baik SH; Choi DS; Kang YS; Han SY; Han KH; Ji YH; Cha DR
Diabet Med; 2004 Jun; 21(6):545-51. PubMed ID: 15154937
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
Shen X; Zhang Z; Zhang X; Zhao J; Zhou X; Xu Q; Shang H; Dong J; Liao L
Lipids Health Dis; 2016 Oct; 15(1):179. PubMed ID: 27733168
[TBL] [Abstract][Full Text] [Related]
37. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
de Zeeuw D
Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of increased serum cytokeratin 19 fragment levels in patients with diabetic nephropathy as a model of chronic renal failure.
Kashiwabara K; Kishi K; Nakamura H; Yagyu H; Kobayashi K; Watanabe O; Matsuoka T
Intern Med; 1998 Nov; 37(11):917-21. PubMed ID: 9868951
[TBL] [Abstract][Full Text] [Related]
39. Increased urinary excretion of non-albumin antigen detected with YO-2, a novel monoclonal antibody, in diabetic patients.
Yonei T; Watarai S; Okada Y; Yasuda T; Tsuji T
Acta Med Okayama; 1995 Jun; 49(3):153-9. PubMed ID: 7676846
[TBL] [Abstract][Full Text] [Related]
40. Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes.
de Carvalho JA; Tatsch E; Hausen BS; Bollick YS; Moretto MB; Duarte T; Duarte MM; Londero SW; Premaor MO; Comim FV; Delanghe JR; Moresco RN
Clin Biochem; 2016 Feb; 49(3):232-6. PubMed ID: 26519090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
